Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

Research and development of a new oral administration of the vaccine in the company AUMED, a.s.

Perorální-aplikace-vakcín4

As part of the 4th public tender in the TRIO program, AUMED has a project for a new version of the human vaccine carrier. The subject of the project is research and development of a new oral administration of the vaccine. The aim of the project is a microbial vaccine in the form of a lyophilized tablet which intended for administration into the oral cavity. A newly innovated pertussis vaccine has been chosen as a model vaccine which was developed by the company AUMED, a.s. in recent years. AUMED, a.s. cooperates on this project with the Charles University, Faculty of Pharmacy in Hradec Králové (Department of Pharmaceutical Technology, Head of Department: doc. PharmDr. Zdeňka Šklubalová, Ph.D.).

The chosen model vaccine is justified in the increasing number of local epidemics of whooping cough even in populations that are vaccinated against an infectious agent. The reason for the failure of the currently used vaccines is to move away from the whole-cell vaccine (due to the higher reactogenicity of the original whole-cell vaccine) and use instead the acellular form of the vaccine as the less reactogenic form. However, the acellular vaccines did not meet the expected long-term protective effect. The phenomenon of increasing number of local epidemics of whooping cough affects not only our region, but also most of Europe and the US. In addition, epidemiological forecasts assume that the current state represents only a “start” of the trend and that in the following years will there be a sharp rise in whooping cough in the population. Moreover, in the context of increasing antibiotic resistance, this is a dramatic outlook that needs to be addressed rapidly by developing new vaccine approaches.

MORE ARTICLES

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s